Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | CHIEF FINANCIAL OFFICER | January 07, 2026 | January 10, 2026 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Chief Financial Officer | May 01, 2026 | May 07, 2026 |
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Financial Officer | May 29, 2020 | June 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,852 |
Ending reported balance
After 2026-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Exercise / conversion · Acquired 6,700 · Balance 24,367 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Row 2 · 2026-01-08 · Sale · Disposed 2,515 · Balance 21,852 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 20,100 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Exercise / conversion · Disposed 6,700 · Balance 20,100 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Arcturus Therapeutics Holdings Inc.
Report date May 01, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2036-05-01 | Direct | 100,000 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
F2: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.
LA JOLLA PHARMACEUTICAL CO
Report date May 29, 2020 · Filed June 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,067 |
Reported balance
After 2020-05-29 transaction · row 1
1 source rowRow 1 · 2020-05-29 · Grant · Acquired 82 · Balance 5,067 F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-05-29 | Direct | 82 |
Reported balance
After 2020-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-29 · Grant · Acquired 82 · Balance 82 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2019 Filed Mar 19, 2019 16:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 49 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0000920465-19-000052 · wf-form4_155302845430209.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49 Underlying: Common Stock · 49 shares Expires 2029-03-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 16:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 49 | $6.49 | $318.01 |
DisclosureSEC source: 0000920465-19-000052 · wf-form4_155302845430209.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214 F1 · kind: These shares were acquired on 3/15/19 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:32 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 65 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000920465-19-000047 · wf-form4_155173871508303.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65 Underlying: Common Stock · 65 shares Expires 2029-02-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:32 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 65 | $4.85 | $315.25 |
DisclosureSEC source: 0000920465-19-000047 · wf-form4_155173871508303.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 F1 · kind: These shares were acquired on 02/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 60 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000920465-19-000036 · wf-form4_155061790150228.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60 Underlying: Common Stock · 60 shares Expires 2029-02-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 60 | $5.30 | $318.00 |
DisclosureSEC source: 0000920465-19-000036 · wf-form4_155061790150228.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: These shares were acquired on 02/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 63 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0000920465-19-000028 · wf-form4_154932198315750.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63 Underlying: Common Stock · 63 shares Expires 2029-01-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 63 | $5.13 | $323.19 |
DisclosureSEC source: 0000920465-19-000028 · wf-form4_154932198315750.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040 F1 · kind: These shares were acquired on 01/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000920465-19-000022 · wf-form4_154847154935676.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:54 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 316 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0000920465-19-000015 · wf-form4_154777643430070.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316 Underlying: Common Stock · 316 shares Expires 2029-01-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:54 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 316 | $5.74 | $1,813.84 |
DisclosureSEC source: 0000920465-19-000015 · wf-form4_154777643430070.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977 F1 · kind: These shares were acquired on 01/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 39 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000003 · wf-form4_154656312983515.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39 Underlying: Common Stock · 39 shares Expires 2028-12-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 39 | $8.02 | $312.60 |
DisclosureSEC source: 0000920465-19-000003 · wf-form4_154656312983515.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661 F1 · kind: These shares were acquired on 12/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 28 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0000920465-18-000068 · wf-form4_154509655405828.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28 Underlying: Common Stock · 28 shares Expires 2028-12-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 28 | $10.88 | $304.64 |
DisclosureSEC source: 0000920465-18-000068 · wf-form4_154509655405828.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622 F1 · kind: These shares were acquired on 12/14/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:57 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 26 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000920465-18-000064 · wf-form4_154389221595075.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26 Underlying: Common Stock · 26 shares Expires 2028-11-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:57 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 26 | $12.30 | $319.79 |
DisclosureSEC source: 0000920465-18-000064 · wf-form4_154389221595075.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594 F1 · kind: These shares were acquired on 11/30/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 24 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0000920465-18-000057 · wf-form4_154266512892385.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24 Underlying: Common Stock · 24 shares Expires 2028-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 24 | $12.67 | $303.96 |
DisclosureSEC source: 0000920465-18-000057 · wf-form4_154266512892385.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568 F1 · kind: These shares were acquired on 11/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:40 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 22 | $0.00 Strike: $16.30 | $0.00 |
DisclosureSEC source: 0000920465-18-000050 · wf-form4_154111923340399.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22 Underlying: Common Stock · 22 shares Expires 2028-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:40 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 22 | $13.86 | $304.81 |
DisclosureSEC source: 0000920465-18-000050 · wf-form4_154111923340399.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544 F1 · kind: These shares were acquired on 10/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 22 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0000920465-18-000043 · wf-form4_153965121899234.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22 Underlying: Common Stock · 22 shares Expires 2028-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 22 | $13.81 | $303.82 |
DisclosureSEC source: 0000920465-18-000043 · wf-form4_153965121899234.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522 F1 · kind: These shares were acquired on 10/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $32.47 | $0.00 |
DisclosureSEC source: 0000920465-17-000091 · wf-form4_151458506789839.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2027-12-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 49,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0000920465-17-000082 · wf-form4_151321721236791.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 16:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 500 | $33.95 | $16,975.00 |
DisclosureSEC source: 0000920465-17-000034 · wf-form4_148883406594117.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:23 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 64,100 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0000920465-17-000017 · wf-form4_148374499579497.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,100 Underlying: Common Stock · 64,100 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 64,100 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on January 4, 2018, with the remaining 48,075 shares vesting monthly thereafter over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.